Chinese General Practice ›› 2023, Vol. 26 ›› Issue (27): 3392-3396.DOI: 10.12114/j.issn.1007-9572.2023.0067
• Article • Previous Articles Next Articles
Received:
2022-10-27
Revised:
2023-03-01
Published:
2023-09-20
Online:
2023-04-03
Contact:
PEI Dongmei
通讯作者:
裴冬梅
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0067
变量 | 例数 | 年龄(岁) | 性别(男/女) | BMI 〔M(P25,P75),kg/m2〕 | 腰围〔M(P25,P75),cm〕 | WBC 〔M(P25,P75),×109/L〕 | HGB 〔M(P25,P75),g/L〕 |
---|---|---|---|---|---|---|---|
A组 | 316 | 52.5±10.0 | 160/156 | 26.2(24.3,27.8) | 91(85,95) | 6.10(5.30,7.28) | 155.00(144.00,164.00) |
B组 | 350 | 53.0±9.7 | 178/172 | 27.2(25.5,28.6)c | 93(88,98)c | 6.50(5.60,7.60)c | 156.00(146.00,164.25) |
C组 | 330 | 51.9±10.3 | 167/163 | 23.5(21.5,25.9)cd | 82(76,90)cd | 5.76(4.80,6.60)cd | 145.50(136.00,156.00)cd |
检验统计量值 | 1.279a | 0.005b | 213.668 | 192.303 | 50.092 | 75.767 | |
P值 | 0.279 | 0.997 | <0.001 | <0.001 | <0.001 | <0.001 | |
变量 | ALT 〔M(P25,P75),U/L〕 | AST 〔M(P25,P75),U/L〕 | ALP〔M(P25,P75),U/L〕 | GGT 〔M(P25,P75),U/L〕 | TG〔M(P25,P75),mmol/L〕 | UA (μmol/L) | TC〔M(P25,P75),mmol/L〕 |
A组 | 20.00(15.25,27.75) | 19.00(16.00,23.00) | 83.50±20.47 | 29.00(20.00,43.00) | 1.70(1.25,2.47) | 384.16±80.76 | 5.14(4.49,5.81) |
B组 | 26.00(18.00,35.00)c | 21.00(17.00,26.00)c | 83.02±21.36 | 37.00(24.75,60.00)c | 1.99(1.53,2.90)c | 409.09±95.66c | 5.15(4.51,5.89) |
C组 | 15.00(11.75,22.00)cd | 18.00(15.00,21.00)cd | 73.22±23.05cd | 19.00(13.00,30.25)cd | 1.18(0.81,1.85)cd | 325.19±101.58cd | 4.94(4.42,5.56)cd |
检验统计量值 | 148.809 | 43.836 | 23.683a | 157.872 | 120.480 | 117.657a | 10.817 |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.004 |
变量 | FPG 〔M(P25,P75),mmol/L〕 | HbA1c 〔M(P25,P75),%〕 | FT3 (pmol/L) | FT4 〔M(P25,P75),pmol/L〕 | TSH〔M(P25,P75),μU/mL〕 | Anti-TPO〔M(P25,P75),U/mL〕 | Anti-Tg〔M(P25,P75),U/mL〕 |
A组 | 5.35(5.02,6.02) | 5.50(5.20,5.90) | 4.70±0.55 | 13.05(12.19,13.90) | 1.66(1.16,2.43) | 0.50(0.22,1.28) | 1.61(1.13,2.64) |
B组 | 5.48(5.14,6.12)c | 5.60(5.30,6.20)c | 4.71±0.54 | 12.68(12.01,13.57) | 1.63(1.15,2.55) | 0.45(0.17,1.35) | 1.60(1.18,2.65) |
C组 | 5.17(4.85,5.62)cd | 5.40(5.09,5.60)cd | 4.61±0.56cd | 12.87(12.03,13.75) | 1.62(1.21,2.35) | 0.53(0.24,1.55) | 1.64(1.11,4.45) |
检验统计量值 | 52.854 | 52.304 | 3.148a | 6.213 | 0.071 | 4.457 | 1.413 |
P值 | <0.001 | <0.001 | 0.043 | 0.059 | 0.965 | 0.108 | 0.493 |
Table 1 Comparison of clinical data among three groups of subjects
变量 | 例数 | 年龄(岁) | 性别(男/女) | BMI 〔M(P25,P75),kg/m2〕 | 腰围〔M(P25,P75),cm〕 | WBC 〔M(P25,P75),×109/L〕 | HGB 〔M(P25,P75),g/L〕 |
---|---|---|---|---|---|---|---|
A组 | 316 | 52.5±10.0 | 160/156 | 26.2(24.3,27.8) | 91(85,95) | 6.10(5.30,7.28) | 155.00(144.00,164.00) |
B组 | 350 | 53.0±9.7 | 178/172 | 27.2(25.5,28.6)c | 93(88,98)c | 6.50(5.60,7.60)c | 156.00(146.00,164.25) |
C组 | 330 | 51.9±10.3 | 167/163 | 23.5(21.5,25.9)cd | 82(76,90)cd | 5.76(4.80,6.60)cd | 145.50(136.00,156.00)cd |
检验统计量值 | 1.279a | 0.005b | 213.668 | 192.303 | 50.092 | 75.767 | |
P值 | 0.279 | 0.997 | <0.001 | <0.001 | <0.001 | <0.001 | |
变量 | ALT 〔M(P25,P75),U/L〕 | AST 〔M(P25,P75),U/L〕 | ALP〔M(P25,P75),U/L〕 | GGT 〔M(P25,P75),U/L〕 | TG〔M(P25,P75),mmol/L〕 | UA (μmol/L) | TC〔M(P25,P75),mmol/L〕 |
A组 | 20.00(15.25,27.75) | 19.00(16.00,23.00) | 83.50±20.47 | 29.00(20.00,43.00) | 1.70(1.25,2.47) | 384.16±80.76 | 5.14(4.49,5.81) |
B组 | 26.00(18.00,35.00)c | 21.00(17.00,26.00)c | 83.02±21.36 | 37.00(24.75,60.00)c | 1.99(1.53,2.90)c | 409.09±95.66c | 5.15(4.51,5.89) |
C组 | 15.00(11.75,22.00)cd | 18.00(15.00,21.00)cd | 73.22±23.05cd | 19.00(13.00,30.25)cd | 1.18(0.81,1.85)cd | 325.19±101.58cd | 4.94(4.42,5.56)cd |
检验统计量值 | 148.809 | 43.836 | 23.683a | 157.872 | 120.480 | 117.657a | 10.817 |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.004 |
变量 | FPG 〔M(P25,P75),mmol/L〕 | HbA1c 〔M(P25,P75),%〕 | FT3 (pmol/L) | FT4 〔M(P25,P75),pmol/L〕 | TSH〔M(P25,P75),μU/mL〕 | Anti-TPO〔M(P25,P75),U/mL〕 | Anti-Tg〔M(P25,P75),U/mL〕 |
A组 | 5.35(5.02,6.02) | 5.50(5.20,5.90) | 4.70±0.55 | 13.05(12.19,13.90) | 1.66(1.16,2.43) | 0.50(0.22,1.28) | 1.61(1.13,2.64) |
B组 | 5.48(5.14,6.12)c | 5.60(5.30,6.20)c | 4.71±0.54 | 12.68(12.01,13.57) | 1.63(1.15,2.55) | 0.45(0.17,1.35) | 1.60(1.18,2.65) |
C组 | 5.17(4.85,5.62)cd | 5.40(5.09,5.60)cd | 4.61±0.56cd | 12.87(12.03,13.75) | 1.62(1.21,2.35) | 0.53(0.24,1.55) | 1.64(1.11,4.45) |
检验统计量值 | 52.854 | 52.304 | 3.148a | 6.213 | 0.071 | 4.457 | 1.413 |
P值 | <0.001 | <0.001 | 0.043 | 0.059 | 0.965 | 0.108 | 0.493 |
项目 | 例数 | TN患病率〔例(%)〕 | χ2值 | P值 |
---|---|---|---|---|
年龄 | 58.844 | <0.001 | ||
≥50岁 | 307 | 139(45.28) | ||
<50岁 | 359 | 64(17.83) | ||
性别 | 6.399 | 0.011 | ||
男 | 338 | 88(26.83) | ||
女 | 328 | 115(35.06) | ||
BMI | 48.716 | <0.001 | ||
≥28.0 kg/m2 | 246 | 115(46.75) | ||
<28.0 kg/m2 | 420 | 88(20.95) | ||
男性腰围 | 6.147 | 0.014 | ||
≥90 cm | 255 | 75(29.41) | ||
<90 cm | 83 | 13(15.66) | ||
女性腰围 | 8.322 | 0.005 | ||
≥85 cm | 233 | 93(39.91) | ||
<85 cm | 95 | 22(23.16) |
Table 2 Comparison of prevalence of thyroid nodules among metabolic-associated fatty liver disease patients with different clinical features
项目 | 例数 | TN患病率〔例(%)〕 | χ2值 | P值 |
---|---|---|---|---|
年龄 | 58.844 | <0.001 | ||
≥50岁 | 307 | 139(45.28) | ||
<50岁 | 359 | 64(17.83) | ||
性别 | 6.399 | 0.011 | ||
男 | 338 | 88(26.83) | ||
女 | 328 | 115(35.06) | ||
BMI | 48.716 | <0.001 | ||
≥28.0 kg/m2 | 246 | 115(46.75) | ||
<28.0 kg/m2 | 420 | 88(20.95) | ||
男性腰围 | 6.147 | 0.014 | ||
≥90 cm | 255 | 75(29.41) | ||
<90 cm | 83 | 13(15.66) | ||
女性腰围 | 8.322 | 0.005 | ||
≥85 cm | 233 | 93(39.91) | ||
<85 cm | 95 | 22(23.16) |
组别 | 例数 | 1类 | 2类 | 3类 | ≥4类 |
---|---|---|---|---|---|
A组 | 316 | 235(74.37) | 59(18.67) | 16(5.06) | 6(1.90) |
B组 | 350 | 228(65.14)a | 67(19.14) | 40(11.43)a | 15(4.29)a |
C组 | 330 | 265(80.30)ab | 58(17.58) | 5(1.51)ab | 2(0.61)ab |
Table 3 Comparison of thyroid nodules classified by C-TIRADS among three groups of subjects
组别 | 例数 | 1类 | 2类 | 3类 | ≥4类 |
---|---|---|---|---|---|
A组 | 316 | 235(74.37) | 59(18.67) | 16(5.06) | 6(1.90) |
B组 | 350 | 228(65.14)a | 67(19.14) | 40(11.43)a | 15(4.29)a |
C组 | 330 | 265(80.30)ab | 58(17.58) | 5(1.51)ab | 2(0.61)ab |
变量 | B | SE | Waldχ2值 | OR值 | 95%CI | P值 |
---|---|---|---|---|---|---|
年龄 | 0.346 | 0.030 | 133.210 | 1.413 | (1.333,1.499) | <0.001 |
BMI | 1.483 | 0.134 | 121.982 | 4.405 | (3.386,5.731) | <0.001 |
ALT | 0.188 | 0.015 | 147.075 | 1.206 | (1.170,1.243) | <0.001 |
TC | 1.924 | 0.160 | 144.827 | 6.851 | (5.008,9.373) | <0.001 |
GGT | 0.081 | 0.007 | 142.991 | 1.085 | (1.070,1.099) | <0.001 |
FPG | 2.337 | 0.202 | 134.135 | 10.346 | (6.967,15.364) | <0.001 |
HbA1c | 2.565 | 0.228 | 126.949 | 12.995 | (8.318,20.301) | <0.001 |
TG | 1.508 | 0.130 | 134.334 | 4.520 | (3.502,5.833) | <0.001 |
UA | 0.038 | 0.003 | 143.321 | 1.039 | (1.033,1.046) | <0.001 |
Table 4 Univariate Logistic regression analysis of influencing factors of thyroid nodules in metabolic-associated fatty liver disease
变量 | B | SE | Waldχ2值 | OR值 | 95%CI | P值 |
---|---|---|---|---|---|---|
年龄 | 0.346 | 0.030 | 133.210 | 1.413 | (1.333,1.499) | <0.001 |
BMI | 1.483 | 0.134 | 121.982 | 4.405 | (3.386,5.731) | <0.001 |
ALT | 0.188 | 0.015 | 147.075 | 1.206 | (1.170,1.243) | <0.001 |
TC | 1.924 | 0.160 | 144.827 | 6.851 | (5.008,9.373) | <0.001 |
GGT | 0.081 | 0.007 | 142.991 | 1.085 | (1.070,1.099) | <0.001 |
FPG | 2.337 | 0.202 | 134.135 | 10.346 | (6.967,15.364) | <0.001 |
HbA1c | 2.565 | 0.228 | 126.949 | 12.995 | (8.318,20.301) | <0.001 |
TG | 1.508 | 0.130 | 134.334 | 4.520 | (3.502,5.833) | <0.001 |
UA | 0.038 | 0.003 | 143.321 | 1.039 | (1.033,1.046) | <0.001 |
变量 | B | SE | Waldχ2值 | OR值 | 95%CI | P值 |
---|---|---|---|---|---|---|
年龄 | 0.370 | 0.072 | 25.995 | 1.447 | (1.255,1.668) | <0.001 |
BMI | 1.046 | 0.245 | 18.252 | 2.847 | (1.762,4.600) | <0.001 |
TG | 1.081 | 0.228 | 22.564 | 2.947 | (1.887,4.603) | <0.001 |
TC | 1.174 | 0.445 | 6.965 | 3.235 | (1.353,7.736) | <0.001 |
FPG | 1.022 | 0.246 | 17.293 | 2.780 | (1.717,4.501) | <0.001 |
HbA1c | 1.215 | 0.268 | 20.558 | 3.371 | (1.994,5.701) | <0.001 |
Table 5 Multivariate Logistic regression analysis of influencing factors of thyroid nodules in metabolic-associated fatty liver disease
变量 | B | SE | Waldχ2值 | OR值 | 95%CI | P值 |
---|---|---|---|---|---|---|
年龄 | 0.370 | 0.072 | 25.995 | 1.447 | (1.255,1.668) | <0.001 |
BMI | 1.046 | 0.245 | 18.252 | 2.847 | (1.762,4.600) | <0.001 |
TG | 1.081 | 0.228 | 22.564 | 2.947 | (1.887,4.603) | <0.001 |
TC | 1.174 | 0.445 | 6.965 | 3.235 | (1.353,7.736) | <0.001 |
FPG | 1.022 | 0.246 | 17.293 | 2.780 | (1.717,4.501) | <0.001 |
HbA1c | 1.215 | 0.268 | 20.558 | 3.371 | (1.994,5.701) | <0.001 |
[1] |
薛芮,范建高. 代谢相关脂肪性肝病新定义的国际专家共识简介[J]. 临床肝胆病杂志,2020,36(6):1224-1227. DOI:10.3969/j.issn.1001-5256.2020.06.007.
|
[2] |
|
[3] |
|
[4] |
施漪雯,肖倩倩,范建高. 亚太肝脏研究协会代谢相关脂肪性肝病临床诊疗指南简介[J]. 中华肝脏病杂志,2020,28(11):915-917. DOI:10.3760/cma.j.cn51113-20201102-00592.
|
[5] |
周建桥,詹维伟. 2020年中国超声甲状腺影像报告和数据系统(C-TIRADS)指南解读[J]. 诊断学理论与实践,2020,19(4):350-353. DOI:10.16150/j.1671-2870.2020.04.005.
|
[6] |
中华人民共和国国家卫生和计划生育委员会. 成人体重判定:WS/T 428—2013[S]. 中国标准出版社,2013.
|
[7] |
|
[8] |
|
[9] |
中国超声医学工程学会浅表器官及外周血管专业委员会. 甲状腺及相关颈部淋巴结超声若干临床常见问题专家共识(2018版)[J]. 中国超声医学杂志,2019,35(3):193-204. DOI:10.3969/j.issn.1002-0101.2019.03.001.
|
[10] |
阮小风,张建军,夏红梅,等. 非酒精性脂肪性肝病与甲状腺结节异病同治理论探析[J]. 中西医结合肝病杂志,2021,31(1):81-82,89. DOI:10.3969/j.issn.1005-0264.2021.01.023.
|
[11] |
|
[12] |
姚宏,胡艳,饶开晴,等. 雌激素-雌激素受体通路影响母鸡脂肪肝发生的可能机制[J]. 动物营养学报,2021,33(1):85-94. DOI:10.3969/j.issn.1006-267x.2021.01.009.
|
[13] |
|
[14] |
|
[15] |
钱巧慧,方琦,郭建,等. 非酒精性脂肪肝患者胰岛素抵抗程度与甲状腺结节的相关性研究[J]. 实用预防医学,2018,25(6):717-719. DOI:10.3969/j.issn.1006-3110.2018.06.021.
|
[16] |
常星宇,傅松波,汤旭磊,等. 脂代谢异常人群甲状腺结节检出情况及相关因素分析[J]. 中华地方病学杂志,2021,40(9):718-723. DOI:10.3760/cma.j.cn231583-20201117-00297.
|
[17] |
王伟. 脂代谢异常人群甲状腺结节的检出情况及相关影响因素研究[J]. 检验医学与临床,2022,19(19):2704-2707. DOI:10.3969/j.issn.1672-9455.2022.19.030.
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[1] | ZHANG Aili, HOU Qiqi, HAN Quanle, ZHANG Boheng, ZHANG Jiawei, CAO Hongxia, ZHANG Chao, CHEN Shuohua, WU Shouling, LI Kangbo. Correlation between Atrial Fibrillation and the Risk of New-onset Chronic Kidney Disease in Northern Chinese Population [J]. Chinese General Practice, 2023, 26(36): 4521-4526. |
[2] | BAI Haiwei, MI Xiaokun, LIU Qingrui, ZHU Lin, WANG Yingnan, LIU Junyan, HAN Ying. Predictive Value of Serum Uric Acid in Perioperative Acute Ischemic Stroke in Patients with Non-small Cell Lung Cancer [J]. Chinese General Practice, 2023, 26(36): 4545-4551. |
[3] | CHU Xiaojing, LI Jun, FU Yanqin, LIU Danqing, LIU Aiping, ZHANG Yuanyuan. Effect of Human Body Composition and Serum Biochemical Indicators on the Accuracy of Flash Glucose Monitoring System [J]. Chinese General Practice, 2023, 26(35): 4433-4438. |
[4] | XIE Xuemei, GAO Jing, BAI Dingxi, LU Xianying, HE Jiali, LI Yue. Current Status of Polypharmacy in the Elderly and Its Influencing Factors: a Meta-analysis [J]. Chinese General Practice, 2023, 26(35): 4394-4403. |
[5] | WANG Yue, CHEN Qing, LIU Lurong. Detection Rate of Depression and Its Influencing Factors in Chinese Elderly: a Meta-analysis [J]. Chinese General Practice, 2023, 26(34): 4329-4335. |
[6] | LI Dianjiang, PAN Enchun, SUN Zhongming, WEN Jinbo, WANG Miaomiao, WU Ming, SHEN Chong. The Current Status and Influencing Factors of Clinical Inertia in Type 2 Diabetes Patients in Community [J]. Chinese General Practice, 2023, 26(34): 4296-4301. |
[7] | HAO Aihua, ZENG Weilin, LI Guanhai, XIA Yinghua, CHEN Liang. Current Situation of the Construction of Family Doctor Team: an Investigation Based on the Perspective of General Practitioners [J]. Chinese General Practice, 2023, 26(34): 4261-4268. |
[8] | QIN Fengyin, ZHANG Qishan, LAI Jinjia, HUANG Yimin, HAN Guoyin, SUN Xinglan, WANG Fen, TAN Yibing. Current Status and Influencing Factors of the Intention to Screen for High-risk Stroke among Community Residents in Guangdong [J]. Chinese General Practice, 2023, 26(34): 4283-4289. |
[9] | LIANG Xuan, NA Feiyang, QIN Mengyao, YANG Hui, GUO Li, GUO Qi, REN Lei, CHEN De, LIU Donghai, ZHANG Rongfang. Clinical Characteristics and Influencing Factors of Bronchial Asthma Combined with Obstructive Sleep Apnea-hypopnea Syndrome in Children [J]. Chinese General Practice, 2023, 26(33): 4225-4230. |
[10] | LI Qianqian, CHEN Xunrui, ZHANG Wenying, YUAN Haihua, ZHANG Yanjie, JIANG Bin, LIU Feng. Demand and Influencing Factors for Community Health Services during Chemotherapy of Patients with Advanced Cancer [J]. Chinese General Practice, 2023, 26(33): 4173-4180. |
[11] | ZHANG Jin, DING Zhiguo, QI Shuo, LI Ying, LI Weiqiang, ZHANG Yuanyuan, ZHOU Tong. Relationship between Serum Thyroid Hormone Levels and Prognosis during Hospitalization in Heart Failure Patients [J]. Chinese General Practice, 2023, 26(33): 4125-4129. |
[12] | WANG Lina, GAO Pengfei, CAO Fan, GE Ying, YAN Wei, HE Daikun. Analysis of the Prevalence and Influencing Factors of Non-alcoholic Fatty Liver Disease in Different Gender Groups [J]. Chinese General Practice, 2023, 26(33): 4143-4151. |
[13] | ZHOU Yuyu, GAO Chuan, CUI Puan, WANG Yaping, HE Zhong. Influencing Factors of Shared Decision Making between Doctors and Patients in Menopausal Hormone Therapy in Patients with Menopausal Syndrome [J]. Chinese General Practice, 2023, 26(33): 4181-4186. |
[14] | WANG Minghuan, LI Yuhong, YU Min, WANG Yougang, YU Qiaozhi, YANG Fangfang, YUAN Dehui, ZHANG Liu. Effect of Allostatic Load on Adverse Pregnancy Outcomes of Women in Late Pregnancy [J]. Chinese General Practice, 2023, 26(32): 4064-4069. |
[15] | YUAN Dehui, LI Yuhong, XIONG Min, YU Min, MA Ruiliang, YANG Fangfang, YU Qiaozhi, WANG Minghuan. Status and Influencing Factors of Allostatic Load in Pregnant Women at Different Trimesters [J]. Chinese General Practice, 2023, 26(32): 4057-4063. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||